From the article:
The study's main limitation was its small size, Dr Gregory Poland, emeritus editor of the journal Vaccine and president of Atria Research Institute, told the New York Times.
However, he added: 'Despite these limitations, they found interesting data that need further study.
we need more money to fund more research
Some were fooled, some were coerced, and then some when militant about it
The last group will not even have anything good at their Estate Sales
>>22614569
Images presented do not support accusation
Repeated accusation demonstrates desperation
General Research #25696 >>20950956
Real Estate Investor Says Nobody Wants to do Business in New York City Following Trump Verdict
by Mike LaChance May. 31, 2024 10:15 pm
Real estate investor Grant Cardone appeared on the fox Business Network this week following the Trump verdict and said that it is going to have far reaching effects on the city’s economy. He suggested that nobody (including him) wants to do business in New York City anymore because they no longer trust the political and legal system there. Cardone says that the people who are invested in his company wouldn’t even allow him to do business there. From FOX Business: “If they can do this to Donald Trump, a former president, regardless of how you feel about the politics, if they can do this to a former president, what can they do to Grant Cardone? What can they do to any other businessman?,” the Cardone Capital founder also chimed in Friday on “Varney & Co.”
Cardone recently pulled his business out of the Empire State and cautioned that Trump’s legal troubles — including a previous $355 million fine in a New York civil fraud case in February — would “wreak financial havoc” on the city.
“I have 15,000 investors with me at Cardone Capital. We’ve raised $1.3 billion. If I went to them today and said, ‘I want to invest in New York City,’ they would not give me money to do that,” the investor argued.
“That’s one of the greatest cities on planet Earth. And nobody wants to go there and do business,” Cardone continued. “I blame the legal system. Clearly, the political system has been weaponized.”
New York City is already struggling under the weight of crime, reduced revenue due to people leaving, and the border crisis.
Now they are also going to deal with fewer investments from people just like Cardone.
This situation is going to have an impact on NYC that will last a long time and in ways that cannot even be seen yet.
https://www.thegatewaypundit.com/2024/05/real-estate-investor-says-nobody-wants-do-business/
Video (3:13)
https://www.youtube.com/watch?v=d1w_bGdJY1Q
Naw, seen it many times. Headline and a link, just a tease
Is baker supposed to take the time to check it out? Meh, why put in effort if the original poster isn't willing?
No
21.6 million veterans fat more able to operate in small units
Anons would be herd of cats with firepower and likely most dangerous to speed limit signs
What are you willing to lose in that bet?
Twirl the vpn again and then let me know what you are willing to lose in the accuracy beet
>No, VPN
Oh? then why the set of one post ID wonders?
>you have no idea the people you communicate with on these breads
Read that back to yourself a few times
You wanted to brag about your accuracy and offered a bet, I asked what you were willing to lose
Pfizer shots cause the clots and myocarditis
Buys company makes drugs to treat heart issues
Pfizer finalizes $6.7 billion acquisition of Arena Pharmaceuticals, gaining key cardiovascular treatments
Michael Walter | March 14, 2022 | Cardiovascular Business | Economics
Pfizer has completed its $6.7 billion acquisition of Arena Pharmaceuticals, finalizing a deal that involves multiple cardiovascular properties. The transaction was first announced back in December 2021.
“Pfizer has been on a journey to become a science and innovation-driven biopharmaceutical company, and this will continue to be our focus,” Aamir Malik, executive vice president and chief business innovation officer of Pfizer, said during a conference call with investors and journalists when the deal was first announced. “As an organization, we have to make thoughtful, well-informed capital allocation decisions when it comes to research and development and mergers and acquisitions and drive innovations and advancements in our business model.”
“Pfizer’s capabilities will accelerate our mission to deliver our important medicines to patients,” Amit D. Munshi, president and CEO of Arena, said in a separate statement. “We believe this transaction represents the best next step for both patients and shareholders.”
Etrasimod, an oral medication developed to treat inflammatory conditions such as ulcerative colitis and Crohn’s disease, is at the center of Pfizer’s acquisition, but the company also gained some assets that could boost care for cardiovascular patients.
One of those assets, temanogrel, is currently being studied as a potential treatment for microvascular obstruction. The other, APD418, is a first-in-class treatment for decompensated heart failure (DHF).
“With approximately 10 million DHF patient hospital visits expected in the U.S. by 2025 and few viable treatment options, we believe that APD418 has the potential to make a significant impact for these patients,” Chris Cabell, MD, Arena's senior vice president and chief medical officer, said in a statement in January 2020 after the medication received the FDA’s fast track designation.
According to the terms of the acquisition, Arena was valued at $100 in cash per share. Arena is now a wholly owned subsidiary of Pfizer, and the company’s shares of common stock are being delisted.
https://cardiovascularbusiness.com/topics/healthcare-management/healthcare-economics/pfizer-finalizes-67-billion-acquisition-arena
Related:The Arena pipeline also includes two clinical-stage cardiovascular drugs. The first, temanogrel, is in Phase 2 testing for microvascular obstruction and Raynaud’s phenomenon secondary to systemic sclerosis. ADP418 is in Phase 2 testing for acute heart failure.
https://medcitynews.com/2021/12/pfizer-6-7b-arena-buyout-complements-rather-than-replaces-jak-drugs/